TICKERNERD
Menu
SRPTSRPTHealthcare · Biotechnology

SRPT Stock Forecast: Sarepta Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$20
−2.71% on the day

The 23 Wall Street analysts covering Sarepta Therapeutics, Inc. hold a median 12-month price target of $20 — -0.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 18 Sept 2026 — in the upper half. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
71 / 100
Median analyst target
$20
Analysts covering
23
Revenue$401.3M−34.3% y/y
Operating income$52.3M
Net income−$4.9M
Free cash flow$196.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
+11.6%
YTD
−6.6%
1Y
+8.6%
From 52W high
−17.8%
From 52W low
+35.3%
$15
$24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sarepta Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Sept 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Accruals
93
Quality
81
Issuance
76
Revisions
46
Volatility
44
Size
35
Momentum
33
Growth
28

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26SRPTHigh $38Median $20Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says23 analysts
7 Buy11 Hold5 Sell
Low $5Median $20High $38

The green dot is the last close — the median target sits −0.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026Piper SandlerMaintainsNeutral$23 → $20
9 July 2026Wolfe ResearchUpgradeOutperform$27
16 Apr 2026HC Wainwright & Co.ReiteratesSell—
26 Mar 2026CitigroupMaintainsSell—
26 Mar 2026NeedhamReiteratesUnderperform—
19 Mar 2026OppenheimerReiteratesOutperform—
13 Mar 2026MizuhoMaintainsOutperform—
10 Mar 2026CitigroupMaintainsSell—
2 Mar 2026HC Wainwright & Co.ReiteratesSell—
27 Feb 2026Wells FargoMaintainsOverweight—
27 Jan 2026HC Wainwright & Co.ReiteratesSell—
23 Jan 2026WedbushMaintainsOutperform—
14 Jan 2026HC Wainwright & Co.ReiteratesSell—
9 Dec 2025WedbushInitiatesOutperform—
5 Nov 2025BarclaysMaintainsEqual-Weight—
5 Nov 2025GuggenheimMaintainsBuy—
5 Nov 2025MizuhoUpgradeOutperform—
5 Nov 2025Wells FargoMaintainsOverweight—
4 Nov 2025BairdMaintainsNeutral—
30 Oct 2025Piper SandlerMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SRPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Sarepta Therapeutics, Inc. returned +8.6% against +16.3% for the S&P 500, dividends included.

SRPT vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Oct 25Jan 26Apr 26Jul 26SRPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−8.1%
Analysts raising
4
Analysts cutting
7
Fundamentals

Sarepta Therapeutics, Inc. (SRPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
45.5×

Cheaper than 16% of US stocks

Price / sales
1.1×

Cheaper than 68% of US stocks

Price / book
1.4×

Cheaper than 58% of US stocks

EV / EBITDA
−140.1×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
−34.3%

Higher than 8% of US stocks

Earnings growth (YoY)
−34.3%

Higher than 15% of US stocks

Gross margin
62.8%

Higher than 76% of US stocks

Operating margin
13.0%

Higher than 69% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−9.5%

Higher than 36% of US stocks

Return on assets
−1.1%

Higher than 39% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sarepta Therapeutics, Inc. (SRPT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sarepta Therapeutics, Inc. has a market value of $2.2B and an enterprise value of $2.5B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter shrank 34.3% year on year.

  • Net income over the same four quarters: −$136.7M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.90.

  • Free cash flow in the twelve months to 30 June 2026: $75.0M.

  • Shares outstanding: 105.6M.

  • Trailing P/E: 45.5×; forward P/E: 7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sarepta Therapeutics, Inc. employs 835 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

SRPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRPTSarepta Therapeutics, Inc.$2.2B
71
URGNUroGen Pharma Ltd.$2.1B
82
OCULOcular Therapeutix, Inc.$2.1B
35
TRVITrevi Therapeutics, Inc.$2.1B
53
PVLAPalvella Therapeutics, Inc.$2.2B
32
NUVBNuvation Bio, Inc.$2.1B
60
ADMAADMA Biologics, Inc.$2.0B
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sarepta Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRPT news & analysis

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

MarketBeat · 15 Sept 2026neutral

At a Morgan Stanley Global Healthcare Conference fireside chat, Sarepta Therapeutics outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1).

Why it matters — A SRPT watcher would care because the update indicates the company's strategic focus on sustaining ELEVIDYS uptake while progressing its next pipeline candidates, FSHD and DM1 treatments, toward anticipated readouts.

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Sarepta Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and the presentation was transcribed and published by Seeking Alpha. The item is a transcript of the company's conference remarks.

Why it matters — A SRPT watcher would care because the transcript offers direct insight into what company leadership communicated to investors and analysts at a major healthcare conference.

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Benzinga · 8 Sept 2026negative

Sarepta Therapeutics shares traded lower on Tuesday after Novartis reported data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1). The stock moved in reaction to the rival's clinical results.

Why it matters — The rival's clinical data is relevant to Sarepta watchers because results from a competing DM1 program could influence the competitive landscape for the disease area.

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

Reuters · 8 Sept 2026negative

Shares of Dyne Therapeutics and Sarepta fell on Tuesday after Novartis' muscle-wasting disorder treatment failed in a trial, stoking investor concern about the prospects of similar therapies for the rare, difficult-to-treat disease.

Why it matters — A failed rival trial has raised investor doubts about muscle disease drug developers, pressuring Sarepta's stock despite the setback occurring at another company.

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

Business Wire · 8 Sept 2026positive

Sarepta Therapeutics announced 25 recipients of its Route 79 Duchenne Scholarship Program for the 2026-2027 academic year. Twenty scholarships will go to individuals living with Duchenne muscular dystrophy and five to siblings of those living with the condition, marking the program's ninth year.

Why it matters — The scholarship program reflects Sarepta's ongoing engagement with and support for the Duchenne community, highlighting the company's commitment beyond its commercial pipeline.

FAQ

Frequently asked questions about SRPT stock

What is the SRPT stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Sarepta Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $5 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRPT stock a buy right now?

Of the 23 analysts covering Sarepta Therapeutics, Inc., 7 rate it a Buy, 11 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Sarepta Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 18 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRPT?

As at 18 Sept 2026, Sarepta Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will SRPT stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies -0.5% from the last close, and Ticker Nerd's factor model ranks Sarepta Therapeutics, Inc. 71 out of 100 as at 18 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRPT stock forecast for 2030?

No analyst covering Sarepta Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $38 over the next 12 months.

How has SRPT stock performed over the past year?

Sarepta Therapeutics, Inc. returned +8.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sarepta Therapeutics, Inc. do?

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders.

What is the latest news on SRPT?

The most recent item we track (MarketBeat, 15 Sept 2026): "Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near". At a Morgan Stanley Global Healthcare Conference fireside chat, Sarepta Therapeutics outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1).

Company

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders. The company develops RNA-targeted therapeutics, siRNA-based treatments, gene therapies, and other genetic medicine modalities designed to address underlying disease mechanisms. Its current portfolio includes approved and commercialized therapies for Duchenne muscular dystrophy, along with additional programs in development for other rare genetic conditions. Sarepta Therapeutics also maintains a broader research and manufacturing platform centered on advancing genetic medicine from discovery through delivery. Based in Cambridge, Massachusetts, the company plays a notable role in the rare disease market by combining therapeutic innovation with a specialized focus on patients who often have limited treatment options.

CEO Dr. Michael E. Severino M.D. · 835 employees · United States · https://www.sarepta.com